Evidence map›Paper›PMID 29681498›Full record

ArticleMolecular cell2018

Distinct Stimulatory Mechanisms Regulate the Catalytic Activity of Polycomb Repressive Complex 2.

Chul-Hwan Lee, Marlene Holder, Daniel Grau, Ricardo Saldaña-Meyer, Jia-Ray Yu, Rais Ahmad Ganai, Jenny Zhang, Miao Wang, Gary LeRoy, Marc-Werner Dobenecker and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 134 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. EPOP and MTF2 activate PRC2 activity through DNA-sequence specificity.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Chul-Hwan LeeDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Marlene HolderSkirball Institute of Biomolecular Medicine, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA.
Daniel GrauSkirball Institute of Biomolecular Medicine, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA.
Ricardo Saldaña-MeyerDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Jia-Ray YuDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Rais Ahmad GanaiDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Jenny ZhangSkirball Institute of Biomolecular Medicine, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA.
Miao WangSkirball Institute of Biomolecular Medicine, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA.
Gary LeRoyDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Marc-Werner DobeneckerLaboratory of Immune Cell Epigenetics and Signaling, The Rockefeller University, New York, NY 10065, USA.
Danny ReinbergDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. Electronic address: danny.reinberg@nyumc.org.
Karim-Jean ArmacheSkirball Institute of Biomolecular Medicine, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA. Electronic address: karim-jean.armache@med.nyu.edu.
New York University · USHoward Hughes Medical Institute · USRockefeller University · US

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
Repression via Facultative HeterochromatinR01CA199652 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI REINBERG, DANNY · 2015 to 2025
$4.2M
Structural and functional analysis of gene silencingR01GM115882 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ARMACHE, KARIM JEAN · 2015 to 2023
$3.4M
Howard Hughes Medical InstituteNCI NIH HHS P30 CA016087NCI NIH HHS R01 CA199652NIGMS NIH HHS R01 GM115882
6 · The paper itself

Abstract

The maintenance of gene expression patterns during metazoan development is achieved, in part, by the actions of polycomb repressive complex 2 (PRC2). PRC2 catalyzes mono-, di-, and trimethylation of histone H3 at lysine 27 (H3K27), with H3K27me2/3 being strongly associated with silenced genes. We demonstrate that EZH1 and EZH2, the two mutually exclusive catalytic subunits of PRC2, are differentially activated by various mechanisms. Whereas both PRC2-EZH1 and PRC2-EZH2 are able to catalyze mono- and dimethylation, only PRC2-EZH2 is strongly activated by allosteric modulators and specific chromatin substrates to catalyze trimethylation of H3K27 in mouse embryonic stem cells (mESCs). However, we also show that a PRC2-associated protein, AEBP2, can stimulate the activity of both complexes through a mechanism independent of and additive to allosteric activation. These results have strong implications regarding the cellular requirements for and the accompanying adjustments in PRC2 activity, given the differential expression of EZH1 and EZH2 upon cellular differentiation.

Indexed as

AnimalsCatalysisCell LineChromatinDNA-Binding ProteinsEnhancer of Zeste Homolog 2 ProteinHEK293 CellsHistonesHumansLysineMethylationMicePolycomb Repressive Complex 2ChromatinDNA-Binding ProteinsEnhancer of Zeste Homolog 2 ProteinHistonesLysinePolycomb Repressive Complex 2AEBP2allosteric activationEZH1EZH2H3K27 methylationPRC2

Identifiers

PMID29681498
PMCPMC5949877
OpenAlexW2767186583

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.